Recently, we conducted pilot studies to explore the therapeutic and radio-sensitizing effects of apigenin on pancreatic ductal adenocarcinoma (PDAC) cells carrying the KRAS G12D mutation, specifically PANC-1 cells. Here, KRAS is linked to pancreatic ductal adenocarcinoma.